Molecular therapy for Pulmonary Hypertension (PAH): Tumor suppressor BMP4 inhibits pulmonary hypertension via induction of PDLIM5, 6/February/2015, 22.41

Molecular therapy for Pulmonary Hypertension (PAH): Tumor suppressor BMP4 inhibits pulmonary hypertension via induction of PDLIM5, 6/February/2015, 22.41

Molecular therapy for Pulmonary Hypertension (PAH): Tumor suppressor BMP4 inhibits pulmonary hypertension via induction of PDLIM5, 6/February/2015, 22.41 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that BMP4, by suppressing the expression of its target gene, it may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “BMP4/PDLIM5 activators may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 500*

Undisclosed information: How BMP4  increases the expression of PDLIM5

To citeBoominathan, Molecular therapy for Pulmonary Hypertension (PAH): Tumor suppressor BMP4 inhibits pulmonary hypertension via induction of PDLIM5, 6/February/2015,  22.41,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org